In another example, in genetically engineered mouse models of KRAS-driven pancreatic ductal adenocarcinomas, the reemergence of tumors after withdrawal of oncogenic KRAS is driven by amplification of YAP. Here, KRAS is linked to pancreatic ductal adenocarcinoma.